More articles from Epigenetics

Noncatalytic EZH2 Activity Is Required in SWI/SNF-Mutant Cancers
Cancer Discovery Jan 2016, 6 (1) 13; DOI: 10.1158/2159-8290.CD-RW2015-224
MLL5 Promotes Self-Renewing Glioblastoma Growth via H3.3 Suppression
Cancer Discovery Jan 2016, 6 (1) 9; DOI: 10.1158/2159-8290.CD-RW2015-231
BAP1 Loss Transforms Mesothelioma Cells in an EZH2-Dependent Manner
Cancer Discovery Dec 2015, 5 (12) OF9; DOI: 10.1158/2159-8290.CD-RW2015-195
H3K36me3-Deficient Cancers Are Sensitive to WEE1 Kinase Inhibition
Cancer Discovery Dec 2015, 5 (12) 1233; DOI: 10.1158/2159-8290.CD-RW2015-210
Epigenetic Silencing of T_H1-Type Chemokines Promotes Tumor Immune Evasion
Cancer Discovery Dec 2015, 5 (12) 1237; DOI: 10.1158/2159-8290.CD-RW2015-209
A Broad H3K4me3 Signature Enriches for Tumor-Suppressor Genes
Cancer Discovery Nov 2015, 5 (11) OF9; DOI: 10.1158/2159-8290.CD-RW2015-166
Combination Therapy with the Epigenetic Drugs JQ1 and SAHA Inhibits PDAC
Cancer Discovery Nov 2015, 5 (11) 1119; DOI: 10.1158/2159-8290.CD-RW2015-186
The Global H3K4 Methylation State Controls Leukemia Stem Cell Fate
Cancer Discovery Sep 2015, 5 (9) 902; DOI: 10.1158/2159-8290.CD-RW2015-140
SIRT1 Mediates the Effects of DOT1L Inhibition in MLL-Rearranged Leukemia
Cancer Discovery Jun 2015, 5 (6) OF12; DOI: 10.1158/2159-8290.CD-RW2015-069
Super-Enhancers Facilitate Gene Regulation by Signaling Pathways
Cancer Discovery May 2015, 5 (5) OF11; DOI: 10.1158/2159-8290.CD-RW2015-056

Main menu